Regeneron Pharmaceuticals has agreed to acquire the assets of bankrupt genetic testing company 23andMe for $256 million. Regeneron pledged to 'ensure compliance with 23andMe's consumer privacy policies and applicable laws with respect to the treatment of customer data.' This is a big loss for 23andMe co-founder and former CEO Anne Wojcicki, who'd been trying to buy the company since last summer.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
